Subgroup evaluations did not indicate that there were any sort of differences in treatment results as a function of age or sex. Social Anxiety Disorder.
The effectiveness of Paroxetine hydrochloride in the treatment of social anxiousness disorder was demonstrated in three 12-week, multicenter, placebo-controlled research studies (Studies 1, 2, and 3) of grown-up outpatients regarding social stress and anxiety disorder (DSM-IV). In these research studies, the effectiveness of Paroxetine hydrochloride contrasted to placebo was evaluated on the basis of (1) the percentage of responders, as specified by a Clinical Global Impression (CGI) Improvement score of 1 (quite boosted) or 2 (considerably enhanced), and (2) alter from standard in the Liebowitz Social Anxiety Scale (LSAS).
Research studies 1 and also 2 were flexible-dose studies comparing Paroxetine (20 to 50 milligrams everyday) as well as sugar pill. Paroxetine showed statistically substantial supremacy over inactive medicine on both the CGI Improvement responder criterion and the Liebowitz Social Anxiety Scale (LSAS). In Study 1, for people which completed to week 12, 69 % of Paroxetine-treated patients as compared to 29 % of placebo-treated patients were CGI Improvement -responders. In Study 2, CGI Improvement responders were 77 % and 42 % for the Paroxetine and placebo-treated people, respectively.
Study 3 was a 12-week research study contrasting dealt with Paroxetine dosages of 20, 40, or 60 mg/day regarding sugar pill. Paroxetine 20 mg was shown to be considerably above placebo on both the LSAS Total Score and the CGI Improvement responder standard; there were styles for supremacy over inactive medicine for the 40 mg and 60 mg/day dose groups. There was no indicator in this research of any type of fringe benefit for dosages more than 20 mg/day.
